CMML is characterized by sustained monocytosis and an overlap of myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) resulting from a cumulative mutational landscape including TET2 (60%), SRSF2 (50%), ASXL1 (40%), and the oncogenic RAS pathway (30%) mutations [103]. Here, TET2 is linked to myeloproliferative disorder.